Clinical relevance of reduced bioavailability of rifampicin.
Bioavailability (BA) of rifampicin (RMP) is a critical factor in successful treatment of tuberculosis. The BA of RMP can be reduced by pharmaceutical factors, patient factors and drug interactions. Failure of treatment and development of drug resistance are potential consequences of reduction in BA and it is necessary to understand and control the factors influencing BA of RMP.
Medical Department, Hindustan Ciba-Geigy Limited, A Novartis Group Company, Mumbai.
A D
AD
Bhatt
J A
JA
Vaz
K A
KA
Padgaonkar
D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D004347:Drug Interactions; D006801:Humans; D012293:Rifampin / Q000493:pharmacokinetics / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy
D000995:Antitubercular Agents; D012293:Rifampin